Connecticut Dept of Children & Families Bans Paxil Tue, 26 Aug 2003 The New Haven Register reports that the Connecticut Department of Children and Families (DCF) is the first state agency to ban the use of Paxil in children to protect from harm. Public disclosure of evidence demonstrating Paxil’s suicide…
A Special Article By Curt D. Furberg, MD, PhD; Arthur A. Levin, MPH; Peter A. Gross, MD; Robyn S. Shapiro, JD; Brian L. Strom, MD, MPH
Alternative Medicine is a national magazine with 165,000 subscribers. It is also sold nationwide on newsstands. Its cover story, Nov/Dec, is Kids & Psychiatric Drugs: BIG PHARMA comes to the classroom!
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and…
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
Every federal oversight agency evaluating FDA’s safety performance has given the agency flunking grades. See:https://ahrp.org/cms/content/view/148/55/
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
The law firm of Baum Hedlund filed a lawsuit against GlaxoSmithKline, the maker of the antidepressant, Paxil, for causing severe heart defects in the newborn son, of a woman prescribed Paxil during her pregnancy.
The Associated Press reports (1, 2 below) that the FDA has just issued new warnings about two additional life-threatening risks induced by SSRI antidepressants: Serotonin Syndrome and Persistent Pulmonary Hypertension in newborn babies.
New Peer-Reviewed Publication Authored By Leading Scientists Provides Comprehensive Review of VNS Therapy Mechanism of Action in Treatment-Resistant Depression
Two probing first rate investigative reports document how psychiatry’s treatments are shaped by "opinion leaders" whose professional recommendations are compromised by their substantial, largely undisclosed, financial ties to drug companies.
Dr. David Healy, a formidable critic of the iron grip pharmaceutical corporations wield on the practice of psychiatry as well as on psychiatry’s deficient journal reports, directs his criticism at drug regulators in an article in the current British Medical Journal (BMJ).
